Onvansertib Uses, Dosage, Side Effects and more
Onvansertib is under investigation in clinical trial NCT03303339 (Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).).
| Attribute | Details |
|---|---|
| Trade Name | Onvansertib |
| Generic | Onvansertib |
| Onvansertib Other Names | Onvansertib |
| Type | |
| Formula | C24H27F3N8O3 |
| Weight | Average: 532.5182 Monoisotopic: 532.215821385 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
